The Department of Oncology Department at Apollo Hospitals, Navi Mumbai is renowned for delivering advanced oncology care tailored to individual patient needs, achieving exceptional outcomes with compassion and precision.
Best Cancer Hospital in Mumbai
Introduction to Oncology Care
Cases Treated and Success Rate:
- Surgical Onco IP (2021 to Nov 2024): 3300
- Medical Onco IP including day care: 11000
- Radiation Onco OP Volume: 3550
- Hemat Onco IP: 3500
- Success Rate: 95%
Top Procedures and Treatments
Types of Oncology Diseases Treated
Breast Cancer
Treating a common malignancy among women with personalized therapies aimed at early detection and diverse treatment options.
Prostate Cancer
Focused on early detection and precision treatment, accounting for high survival rates with surgical and radiation advances.
Lung Cancer
Combining systemic and targeted therapies for optimal management, especially crucial given its leading cause of cancer-related deaths globally.
Colorectal Cancer
Delivered through advanced surgical and chemotherapy techniques to ensure quick recovery and improved survival rates
Melanoma
Known for its potential aggressiveness, tackled through therapies enhancing body's immune response against tumor cells.
Thyroid Cancer
Addressing rising incidences with expert care involving advanced diagnostics and surgical interventions.
Maxillofacial Cancer
Combines expertise in surgery and radiation to ensure precise eradication and functional rehabilitation.
Bone & Soft Tissue Cancer
Employing comprehensive approaches involving surgery, chemo, and radiation to preserve limb function and life quality.
Sub-Specialities in Oncology
Head & Neck Oncology
Dedicated to treating cancers of the oral cavity, pharynx, and larynx with innovative surgical techniques and adjuvant therapies.
Breast Cancer
Focused on personalized care integrating surgery, systemic therapy, and reconstruction, ensuring holistic treatment aligned with patient preferences.
Rare Cancer
Specialized treatments for less common cancers ensuring clinical expertise and access to cutting-edge research and personalized therapy options.
Pediatric Hemato Oncology
Providing compassionate, comprehensive care for children with blood-related cancers, emphasis on tailored treatment and minimal long-term effects.
Cutting-Edge Technology and Advantages
Robotic Surgeries
Utilized in GI, GYN, and URO sectors, enhancing precision and minimizing recovery times through minimally invasive procedures.
CAR T Therapy
Revolutionary genetic modification approach to treat specific lymphoma and leukemia types by re-engineering patient’s own immune cells.
Immunotherapy
A paradigm shift in cancer treatment by empowering the immune system to target and eliminate cancer cells particularly in cases resistant to traditional methods
Radiation Techniques
Include TBI, TMLI for comprehensive care, SRS and SBRT for precise tumor targeting, and Rapid Arc for efficient delivery in less treatment time.
Rare Cancer Treatments
Customized protocols based on clinical research to tackle unique and less common cancer manifestations.
Brachytherapy
Involves placing radiation sources close to or inside the tumor, delivering high doses while sparing healthy tissues.
Tumor Board
Multidisciplinary team reviews complex cases providing tailored treatment plans ensuring holistic patient care
Da Vinci and Truebeam STx
Incorporating cutting-edge robotics and radiation infrastructures for precise surgical and oncological interventions.
3D-CRT
Three-Dimensional Conformal Radiation Therapy shaping radiation beams to match tumor dimensions, enhancing accuracy.
Diagnostics and Tests
Research and Innovation
Ongoing Clinical Trials: 1
Published Papers:
- Nair NS, Ali BA, Siddique S, et al. ""Patient Related Awareness of Impact of Cancer-Directed Therapy on Fertility in Young Women Diagnosed of Breast Cancer."" South Asian J Cancer.
- Nair NS. ""Access to HER2 targeted therapy at a tertiary care centre in India: An evolution."" Indian Journal of Cancer.
- Bajpai J, Kapu V, Rath S et al. ""Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumors: A single-centre, open-label, non-inferiority, randomized, controlled, phase 3 trial."" The Lancet Oncology.